Apraglutide 阿帕拉格鲁肽 GLP-2类似物短肠综合征研究 ≥98%

Apraglutide

询价 10g 起订

广东更新日期：2026-05-25

深圳市兆科生物技术有限公司

非会员

联系人：Jade Cheung

手机：19842673490 拨打

邮箱：jade.cheung@zhaokebio.com

产品详情:

中文名称：: 阿帕拉格鲁肽

英文名称：: Apraglutide

CAS号：: 1295353-98-8

保存条件：: 储存于-20°C，避光防潮

纯度规格：: 98.57%

产品类别：: 医药级别

CAS编号：: 1295353-98-8

分子式：: C177H274N48O61S

含量纯度：: 91.7%

英文名称：: Apraglutide

储藏：: 储存于-20°C，避光防潮

单杂：: <= 0.5%

Apraglutide (阿帕拉格鲁肽) is a next-generation, long-acting glucagon-like peptide-2 (GLP-2) analog designed for the treatment of short bowel syndrome (SBS). It features a unique structural modification with an extended half-life, allowing for once-weekly dosing while promoting intestinal adaptation, enhancing nutrient absorption, and reducing parenteral support dependency in SBS patients.

阿帕拉格鲁肽是一种新一代长效胰高血糖素样肽-2（GLP-2）类似物，专为治疗短肠综合征（SBS）而设计。它具有独特的结构修饰，半衰期延长，可实现每周一次给药，同时促进肠道适应、增强营养吸收并减少SBS患者对肠外支持的依赖。

CAS Number	1295353-98-8
Molecular Formula	C177H274N48O61S
Molecular Weight	4059.43 g/mol
Sequence	Long-acting GLP-2 analog with structural modifications for extended half-life and enhanced GLP-2R selectivity
Appearance	White to off-white lyophilized powder
Solubility	Soluble in water and dilute aqueous buffers
Storage	Store at -20°C, protected from light and moisture
Pharmacological Class	GLP-2 receptor agonist
Indication	Short bowel syndrome (SBS); intestinal rehabilitation and parenteral support reduction
Administration Route	Subcutaneous (SC) injection once weekly
Purity	>= 98.0% (by HPLC)

特点 Feature	说明 Description	客户价值 Value
Once-Weekly GLP-2 Analog 每周一次GLP-2类似物	Next-generation long-acting GLP-2 analog with extended half-life enabling convenient once-weekly subcutaneous dosing for SBS patients. 新一代长效GLP-2类似物，半衰期延长，可实现短肠综合征患者每周一次便捷皮下给药。	Addresses the major treatment burden of daily injections in SBS management, significantly improving patient quality of life and adherence. 解决SBS管理中每日注射的主要治疗负担，显著改善患者生活质量和依从性。
Intestinal Rehabilitation 肠道康复	Promotes intestinal adaptation by stimulating crypt cell proliferation, enhancing nutrient absorption surface area. 通过刺激隐窝细胞增殖促进肠道适应，增强营养吸收表面积。	Reduces dependency on parenteral nutrition support - the primary therapeutic goal in short bowel syndrome management. 减少对肠外营养支持的依赖——短肠综合征管理的主要治疗目标。
Structural Innovation 结构创新	Engineered with specific amino acid substitutions for enhanced GLP-2 receptor selectivity and proteolytic stability. 通过特定氨基酸替换进行工程化设计，增强GLP-2受体选择性和蛋白水解稳定性。	Superior receptor binding profile and metabolic stability compared to native GLP-2 and first-generation analogs. 与天然GLP-2和第一代类似物相比，具有更优的受体结合特征和代谢稳定性。
Orphan Disease Focus 孤儿病聚焦	Targets short bowel syndrome, a rare and serious condition with limited therapeutic options and high unmet medical need. 靶向短肠综合征，一种治疗选择有限且医疗需求未得到满足的罕见严重疾病。	Orphan drug designation potential with favorable pricing dynamics and dedicated market exclusivity provisions. 具有孤儿药资格认定潜力，定价动态有利，享有专门的市场独占权条款。
Clinical Validation 临床验证	Demonstrated efficacy in promoting intestinal adaptation and reducing parenteral support requirements in clinical studies. 在临床研究中证明促进肠道适应和减少肠外支持需求的疗效。	Growing clinical evidence package supports development partnerships for global registration and market access. 不断增长的临床证据包支持全球注册和市场准入的开发合作伙伴关系。
GMP Supply Ready GMP供应就绪	Available from research-grade to GMP-compliant API with comprehensive CMC documentation and validated analytical methods. 从研究级到GMP合规API均可提供，附带全面CMC文件和经过验证的分析方法。	Supports seamless progression from preclinical studies through clinical trials to commercial launch for SBS therapeutics. 支持短肠综合征治疗药物从临床前研究到临床试验再到商业上市的无缝推进。
End-to-End Sourcing 端到端采购	Single-source supply of Apraglutide API, reference standards, bioassay methods, and regulatory submission packages. 阿帕拉格鲁肽API、对照品、生物测定方法和法规申报包的单一来源供应。	Reduces procurement complexity and accelerates development timelines for formulation partners and specialty pharma companies. 降低采购复杂性，加速制剂合作伙伴和专业制药公司的开发时间表。